Search

395 Result(s)
Sort by

Being a better ally at work

Being a better ally at work

We’re always identifying ways to be better allies to one another at our family-owned company.
Edda Dankmeyer

Edda Dankmeyer

Edda Dankmeyer leads Sustainable Development Communications and explains how sustainable development can bea key differentiator for the company.
Ways we’re protecting the planet

Ways we’re protecting the planet

Click here to read a few examples of the sustainability practices we’ve put in place at our U.S. HQ, to protect the planet for a more sustainable tomorrow.
Work life wellness

Work life wellness

We provide you with a range of benefits and services, including counselling, exercise classes, social events to help you stay mentally and physically fit.
Our Culture of Caring: Volunteering

Our Culture of Caring: Volunteering

At BI we are committed to improving the health and well-being of people & animals. We encourage & support employee volunteer activities.
Animal Health: Our Responsibility

Animal Health: Our Responsibility

BI's commitment to animal health is reflected in our more than 100 years of successful company history. It is also at the core of sustainability.
Investigating MDM2-p53 in cancer

Investigating MDM2-p53 in cancer

Our most advanced oncology asset in development is being clinically investigated as a potential treatment for people with dedifferentiated liposarcoma.
More Health Overview

More Health Overview

Working at the intersection of human and animal health, we have unique opportunities to positively impact vulnerable populations.
More Green | Sustainable Development

More Green | Sustainable Development

Our MORE GREEN pillar encompasses initiatives that consider many different aspects: adopting measures to avoid water and air pollution, & much more.
Dan’s Unique Story

Dan’s Unique Story

Each cancer journey is unique. In 2018 Dan was diagnosed with a rare form of sarcoma called dedifferentiated liposarcoma. Learn more about Dan’s unique approach to life with DDLPS.
Boehringer Ingelheim and OSE Immunotherapeutics Announce Dosing Of the First Patient in a Phase 1 Trial of SIRPα Antagonist Monoclonal Antibody, BI 765063, in Patients with Advanced Solid Tumors

Boehringer Ingelheim and OSE Immunotherapeutics Announce Dosing Of the First Patient in a Phase 1 Trial of SIRPα Antagonist Monoclonal Antibody, BI 765063, in Patients with Advanced Solid Tumors

Boehringer Ingelheim and OSE Immunotherapeutics Announce Dosing Of the First Patient in a Phase 1 Trial of SIRPα Antagonist Monoclonal Antibody, BI 765063, in Patients with Advanced Solid Tumors